What to Look For in the Pipeline, Misconceptions of Drug Approvals and More of ‘What’s on the Mind’ of Jeffrey Casberg

In this episode, Briana Contreras, an editor with Managed Healthcare Executive, and Peter Wehrwein, managing editor of MHE, got to chatting with the newest editorial advisory board member, Jeffrey Casberg, who is vice president of Clinical Pharmacy at IPD Analytics. 

In the discussion, Casberg shared the most pressing or prominent issues on his mind, he explained what the drug life-cycle is at IPD, and what the latest is on drugs in the pipeline. Casberg also shared his predictions for Sarepta Therapeutics’ DMD drug for young children and Mounjaro’s Type 2 Diabetes Drug, and even touched on some common misconceptions he notices about drug approvals, pricing and cost.